# Supplemental figure 1. Temperature and weight curves in monkeys after high dose *M*. *tuberculosis* infection

Non-vaccinated, BCG vaccinated and BCG vaccinated/H56 boosted monkeys were infected with
 *M.tuberculosis* (500 CFU) and evaluated from 0-64 weeks (every 4 weeks) post challenge. Weight

5 and temperature of the individual animals were determined at the indicated time points.



# 15 Supplemental figure 2. IL-2 ELISPOT after vaccination

IL-2 ELISPOT was performed on 200,000 PBMCs/well from BCG and BCG vaccinated/H56
boosted monkeys, stimulated with Ag85B, ESAT-6, Rv2660c, media (negative control, not shown)
or CFP (culture filtrate proteins) for 48 hours as described in materials and methods.



## 21 Supplemental figure 3. Primer and probe sequences.

- 22 flanking forward (ff) and flanking reverse (fr) for pre-amplification, forward (f) and reverse, (r)
- 23 primers and TaqMan probe (p) for real-time PCR.
- 24
- 25

#### Rv2660c:

- (ff) gcagcaacaggccaggctag, (fr) acaaaatctgggctgcgtgaac,
- (f) gcggcaggcgcatct,
- (r) gaactgactcggtgcaacca,
- (p) tgcccacgccgaca.

#### Rv3875:

- (ff) ggaagcagtccctgaccaagctc,
- (fr) gccttcggtcgaagccattg,
- (f) accagggtgtccagcaaaaatg,
- (r) accggcttcgctgatcgt,
- (p) agctgaacaacgcgctg.

### Rv1886c:

- (ff) ggtactaccagtcgggactgtcgatag,
- (fr) cctgttggcggacaaccattg,
- (f) gcgggcagtccagcttctac,
- (r) ggtcaggaaggtttcccacttg,
- (p) ctgcggtaaggctgg.

#### Rv2225:

- (ff) gcgcacatgcggtcaagct,
- (fr) gcgtcggcgatggtttgttc,
- (f) ccgagcaaatcgcctgtct,
- (r) gccgcccaaggtgttg,
- (p) tgatggcacacatcg.

#### Rv3051c:

- (ff) catatcaagtcggtgccctcaatc,
- (fr) tgcccgcaacgcgtgatac,
- (f) gatcgggctaggacagatgaac,
- (r) ggtgaagtcgatgccttcgt,
- (p) ccgggaacgcatct.

### Rv3127:

- (ff) caaagacgttgcgatgcttgatg,
- (fr) ggcgtctgatgccagcgtatc,
- (f) cgactggtggtagcgtcaca,
- (r) ggtgaagtccaccattcgagtt,
- (p) cgggacgatccgtac

## 25 Supplemental figure 4. Antigen specific IFN-γ ELISPOT responses in individual monkeys.

Frequency of IFN- $\gamma$  producing T cells specific for vaccine antigens is elevated prior to challenge and early (<4 weeks) post-challenge in the BCG/H56-vaccinated animals that would become latent (N=6), but low or absent in the BCG/H56-vaccinated animals (N=2) that developed active TB. The top 3 panels show responses (IFN- $\gamma$  ELISPOT) from the animals that developed active disease; three antigens are shown (ESAT-6, Ag85B, Rv2660c) and each line represents an individual monkey. The bottom 3 panels show the responses from the monkeys who developed latent infection; each line represents an individual monkey.





34

35	Supplemental table 1. Clinical parameters for individual animals after high dose challenge
36	Non-vaccinated, BCG vaccinated and BCG vaccinated/H56 boosted monkeys were infected with

*M.tuberculosis* (500 CFU) and evaluated from 0 to 64 weeks (every 4 weeks) post challenge.
Weight and temperature of the animals were determined at the indicated time points. Erythrocyte
sedimentation rates were determined on whole blood. X-ray: the animals were scored according the
following definitions: (-): negative, SN: scattered nodules, BP(u): unilateral bronchopneumonia,
BP(b): bilateral bronchopneumonia, BP/Con: Bronchopneumonia with consolidation of lung ,



		Non V	acc					BCG						BCG/	H56				
43	Weeks	3008 L	5566 E*	8197 A	2861 I	7156 C	6651 D	7705 B	6784 C*	7947 B	197 BJ	4418 J	5985 C	8262 A	S 4708 EC	5923 D	S 2934 N	7531 C	1290 GB
	0	2,35	2,6	2,6	2,3	2,65	3,2	2,85	2,3	2,45	2,2	2,6	2,8	2,7	2,1	2,75	2,2	2,3	2,35
	8	3,05	2,4	2,7	2,55	2,15	2,5	2,75	2,5	2,55	2,15	2,05	2,03	2,7	2,13	2,65	2,23	2,35	2,55
44	16 20	2,95	2,45	2,8	2,7	2,4	2,5	2,9	2,55	2,65	2,2	2,6	2,95	2,5	2,3	2,95	2,35	2,4	2,65
	24	2,23	2,8	2,03	2,35	2,5		3,1	2,55	2,13	2,35	2,8	3,2	3,	2,45	3,05	2,40	2,05	2,75
	28	2,55	2,65	2,65	2,05	2,55		3	2,5		2,35	2,6	3,15	2,85	2,35	3,1	2,4		2,7
45	32	2,35	∠,4	∠,0	2,4	2,55		2,0	2,4		2,25	2,55	3,05	2,00	3 2,25	3,25	2,25		2,9
15	40							3	2,5			2,95	3,35		3 2,3	3,4	2,55		2,9
	44							2,75	2,6			2,9	3,25	3,0	2,45	3,7	2,5		2,95
16	52								2,7			3,2	3,45	3,2	2,6	3,35	2,75		3
40	60 64								2,55			3,25	3,45	3,0	2,6	3,55	2,55		2.9
47	Weeks	3008 L	5566 E* 38 1	8197 A 38 2	2861 I 37 6	7156 C	6651 D	7705 B	6784 C*	7947 B 36.4	197 BJ 37 1	4418 J	5985 C	8262A	S4708EC	5923D	S2934N	7531C 36.5	1290GB
	4	38,3	38,5	38,3	39,6	37,7	36,2	37,9	37,3	37	37,3	36,8	37,4	38,	38,1	37,5	38,2	37,7	37,5
	8	39,3	38,2	38,3	38,8	37,9	38,6	38,2	38,1	37,8	38,2	38,5	38 5	38,5	38,5	38,2	38	37,4	38
18	20	38,8	36,9	39,1	38	38,6	50,5	37,5	38,4	35,5	38,5	38,4	34,7	37,5	5 38,6	37,5	37,8	37,6	38,1
-0	24	38	39	39,3	37,6	38,2		37,5	37,8		37,9	38,4	37,6	38,6	38,3	37,8	38,3	38,4	38,1
	32	36,7	34,4	37,8	37,6	37,5		37,6	37,0		37,0	38	37,9	38,3	3 38,2	37,3	37,9		37,3
10	36	36,8			38	38,6		37,9	37,8		37,8	38,7	37,9	38,1	38,2	38	37,4		38
49	40							30,3	38			37,1	37,5	37,0	37,8	37,8	37,2		37,1
	52								37,5			37,2	36,5	37,4	38,4	37,9	38		37,8
-0	60								38,4			37,5	38,3	38,3	2 38	37,8	37,1		37,2
50	64								38,3			37,5	38,2	38	38,2	37,9	37,8		37,5
	Wooks	2008.1	EEEE E*	9197 A	2961	71EE C	SSE1 D	7705 B	6794 0*	7947 B	197 B I	4419 1	E995 C	9262.4	S 4709 EC	E923 D	C 2934 N	7531.0	1290 CB
- 4	VVCCK3	0000 L	0	1	20011	1 1 1 1 1	005110	1105 0	0/04 0	1341 0	157 55	4410.0	0	0202 A	0 0	00200	3 2004 14	1551 0	1230 00
51	4	0	0	2	0	0	0	1	0	0	0	0	2		0 0	0	0	1	1
	8	5	0	0	0	0	0	0	0	1	0	0	0	(	0 0	0	0	1	1
	20	0	3	0	0	2		1	0	3	1	0	0	(	0 0	0	0	13	0
52	24	0	21	2	0	7		0	0		0	0	1			0	0	5	0
	32	0	9	24	Ő	2		0	0		7	Ő	0	(	0 0	Ö	0		1
	36 40	20		11	2	2		1	0		10	0	0		0 0	1	1		0
53	44								1			3	1	(	0 0	Ő	0		1
	48								0			0	0	(	0 0	0	0		1
	56								0			Ő	0	(	0 0	Ő	0		0
54	60 64								0			0	0		0 1	1	0		0
									-			-	-		-				-
	Weeks	3008 L	5566 E	8197 A	2861 I 7	7156 C	6651 D	7705 B	6784 C	7947 B	197 BJ	4418 J	5985 C	8262 A	S 4708 EC	5923 D	S 2934 N	7531 C	1290 GB
55	0	(-)	(-)	(-)	(-) (	-)	(-)	(-)	(-)	(-)	(-)	(-)	(-)	(-)	(-)	(-)	(-)	(-)	(-)
00	4	BP(u)	BP(u) BP(b)	(·)	(-) ( (-) (-)	-)	(-) BP(u)	(-) (-)	SN	(-) (-)	(-) (-)	(-)	(-)	(-)	(-)	(-) (-)	(-) (-)	(-) (-)	(-) (-)
	16	(-)	BP(b)	BP(At)	(-) E	./ 3P(b)	BP(u)	(-)	SN	BP(u)	BP(b)	(-)	(-)	(-)	(-)	(-)	(-)	BP(b)	(-)
56	20	(-) SN	BP(b) BP(b)	BP BP/At	(-) E SN E	3P(b) 3P(b)		(-)	SN	BP(b) BP(b)	BP(b) BP(b)	BP(u) BP(u)	(-)	SN (.)	(-)	(-) (-)	(-) (-)	BP(b) BP/Con	(-)
50	28	SN	BP(b)	BP/At	BP(u) E	3P(b)		(-)	SN	01 (0)	BP(b)	BP(u)	(-)	(-)	(-)	(-)	(-)	DIVOOI	(-)
	32	(-)	BP(b)	BP/At BP/At	BP(u) B	3P(b)		(-)	SN		BP(b) BP(Con	BP(u)	(-)	(-)	0	(-)	(-)		(-)
57	40	V/			Dr (u) L	(v) i		(-)	SN		BP/Con	BP(u)	(-)	(-)	(-)	(-)	(-)		(-)
57	48								SN BR(u)			BP(u)	(-)	(-)	(-)	(-)	(-)		(-)
	52								(-)			BP(u)	(-)	(-)	6	(-)	(-)		(-)
	60								(-)			BP(u)	(-)	(-)	(-)	(-)	(-)		(-)
58	64								17			0P'(U)	(7)	(*)	U)	0	57		0

# 59 Supplemental table 2. Pathology scores at necropsy after high dose challenge

60 Gross pathology in lungs and other organs. Pathology scores (maximum score is 10) given as

61 individual organ scores of lungs and other organs in the vaccine and control groups after infection

62	with <i>M. tuberculosis</i> .	"Additional	organs"	include Pericardium,	Stomach and bone.

	Animal number	SCORE	RT. LUNG	LF. LUNG	SPLEEN	KIDNEY	LIVER	PERICARDIUM	STOMACH	BONE	THORACIC LYPMH N.
63	Non-vacc.										
	6651 D	22	7	7	7	0	0	0	0	0	1
64	3008 L	19	3	0	3	0	7	0	0	6	0
	5566 E	24	7	6	3	0	4	0	0	4	0
	8197 A	30	10	7	4	0	5	0	0	4	0
<b>CF</b>	2861 I	08	2	2	0	2	0	0	0	0	2
65	7156 C	16	4	4	3	3	2	0	0	0	0
	BCG										
66	7705 B	02	0	2	0	0	0	0	0	0	0
00	6784 C	00	0	0	0	0	0	0	0	0	0
	7947 B	27	10	9	5	3	0	0	0	0	0
67	197 BJ	35	10	7	0	5	7	2	0	4	0
07	4418 J	09	7	0	2	0	0	0	0	0	0
	5985 C	00	0	0	0	0	0	0	0	0	0
68	BCH/H56										
	8262 A	00	0	0	0	0	0	0	0	0	0
69	S4708 EC	00	0	0	0	0	0	0	0	0	0
	5923 D	00	0	0	0	0	0	0	0	0	0
	S2934 N	05	0	5	0	0	0	0	0	0	0
70	7531 C	34	10	10	4	0	3	0	0	4	3
	1290 GE	00	0	0	0	0	0	0	0	0	0